eli lilly phase 3 trial retatrutide Today, we shared new data from the latest study of retatrutide, an investigational treatment being studied for adults with obesity or overweight with at least one weight-related comorbidity. Learn more Eli Lilly retatrutide Phase 3

Massi, D., Mihic-Probst, D., Schadendorf, D., Dummer, R

AOD 9604 and Semaglutide Semaglutide is an FDA-approved glucagon -like peptide-1 receptor agonist (GLP-1 RA) that is sold in the market under 3 different brand names

I know you do this on your podcast so Im open to it

The opioid receptor hypothesis A separate line of work proposed that DSIP possesses agonist activity at opiate receptors a hypothesis explicit in the title of the principal human withdrawal paper, which describes DSIP as a neuropeptide with potential agonistic activity on opiate receptors. [13] Supporting animal evidence came from Scherschlichts group, where DSIP at 25.5 mcg/kg IV attenuated naloxone-precipitated withdrawal jumping in morphine-dependent mice